---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-018664"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:43:59.407674+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics exchanges 2.5M common shares for Series A convertible preferred with Blue Owl

## Summary
- Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares (10:1 conversion ratio).
- Series A preferred has no voting rights except as required by law and ranks pari passu with common on liquidation.
- Certificate of Amendment increased authorized Series A preferred from 250,000 to 500,000 shares.
- Exchange expected to close Jan 23, 2026, exempt from registration under Section 3(a)(9) of the Securities Act.
- Preferred shares are convertible into up to 2.5M common shares, subject to beneficial ownership limitations.

## SEC filing metadata
- accession: 0001193125-26-018664
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312526018664/0001193125-26-018664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312526018664/d27699d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-018664
- JSON: https://secwatch.observer/filing/0001193125-26-018664.json
- Plain text: https://secwatch.observer/filing/0001193125-26-018664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.